Targeting DED: Multiple Treatment Strategies for a Multifactorial Disease (Virtual CME Symposium)

April 7, 2024

To register for the symposium or claim your credit, please click Register/Take Course.

Sunday, April 7, 2024
6:30 PM – 8:00 PM ET CME Symposium and Virtual Broadcast

Target Audience

This educational activity is intended for ophthalmologists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Incorporate diagnostic strategies for DED into practice
  • Review the pathophysiologic factors of DED
  • Design evidence-based treatment plans for patients with DED
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Course opens: 
03/08/2024
Course expires: 
07/07/2024
Event starts: 
04/07/2024 - 6:30pm EDT
Event ends: 
04/07/2024 - 8:00pm EDT
Add to calendar: 

Faculty

Marjan Farid, MD (Chair)
Professor of Ophthalmology
Director of Cornea, Cataract, and Refractive Surgery
Gavin Herbert Eye Institute
University of California, Irvine
Irvine, California

Jennifer Loh, MD
Founder
Loh Ophthalmology Associates
Clinical Faculty
Larkin Hospital
Ophthalmology Residency
Board Member
Eye Physicians of Florida LLP
Miami, Florida
Parag A. Majmudar, MD
Associate Professor of Ophthalmology
Rush University
Chicago Cornea Consultants
Chicago, Illinois

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

Faculty

Marjan Farid, MD, is a consultant for AbbVie Inc, Alcon, Aldeyra Therapeutics*, Bausch & Lomb Incorporated, Bio-Tissue, Carl Zeiss Meditec, Inc, CorneaGen, Harrow, Inc, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation*, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, and Tarsus Pharmaceuticals, Inc; is an advisory board member of AbbVie Inc, Alcon, Aldeyra Therapeutics*, Bausch & Lomb Incorporated, Bio-Tissue, Carl Zeiss Meditec, Inc, CorneaGen, Harrow, Inc, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation*, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, and Tarsus Pharmaceuticals, Inc; and is a stockholder or has stock options in Kala Pharmaceuticals.

Jennifer Loh, MD, is a consultant for AbbVie Inc, Alcon, Amgen Inc, Bausch & Lomb Incorporated, Beaver-Visitec International, Bio-Tissue, C. Light Technologies, Inc, Centricity Vision, Inc, Dompé US, Inc, Johnson & Johnson Vision Care, Inc, Orasis Pharmaceuticals, Sight Sciences, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Visus Therapeutics, and Zeiss; is an advisory board member of NovaBay Pharmaceuticals, Inc, and Ocular Science; is on the speakers bureau for Alcon, Bausch & Lomb Incorporated, Sight Sciences, and Sun Pharmaceutical Industries, Inc; and is a contracted researcher for Aperta Biosciences, LLC, and Sight Sciences.

Parag A. Majmudar, MD, is a consultant for Alcon, Bausch & Lomb Incorporated, Dompé US Inc, Novaliq GmbH, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, and Zeiss.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

MedEdicus planners and managers have no relevant commercial relationships to disclose.

* The financial relationship existed during the past 24 months but has now ended

Accreditation Statement

MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from Bausch & Lomb Incorporated.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of  MedEdicus LLC or Bausch & Lomb Incorporated.

This CME activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 319.3

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Please login or register to take this course.

Please login if you already have an account on the MedEdicus Learning Portal OR Register to create an account and sign up for this symposium.

If you do not receive an email confirmation, please check your spam folder or email info@mededicus.com.